Clinical management of a Nigerian patient affected by sickle cell disease with rare blood group and persistent SARS‐CoV‐2 positivity

Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature

“… n/a 0 (0) Parodi et al [ 89 ] Italy 2 (1/1) 1.2 HbSS (2) BT (2) Severe SARS-CoV-2 infection revealed a hidden condition of SCD. n/a 0 (0) Quaresima et al [ 90 ] Italy 1 (0/1) 18 HbSS HU (1) BT (1) Pt had ACS and abnormal chest CT but no resp. symptoms, remained COVID-19 pos for a long time, and rare blood type prohibited BT.…”

“…In the general population, children are less likely to experience severe COVID-19 outcomes as compared to adults [ 76 ], but only few studies [ 29 , 72 ] have examined children with SCD and SARS-CoV-2 infection in sufficiently large cohorts from which valid inference can be drawn, as the vast majority of studies were case reports with less than 10 patients [ 67 , 68 , 75 , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , [90] , [91] , [92] ].…”

“…It was hypothesized that activation of the type I Interferon (IFN-I) pathway may have contributed to partial protection from SARS-CoV-2 severe illness and death seen in their pediatric sample. Among the smaller pediatric studies [ 67 , 68 , 75 , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , [90] , [91] , [92] ] that reported on a combined 42 children with SCD, there was 1 (2.4%) patient with a history of prior pulmonary and cardiac complications who died from COVID-19 disease.…”

“…Table 4 summarizes the study parameters and main findings of 7 observational cohort studies [ 28 , [38] , [39] , [40] , [95] , [96] , [97] ] and 4 case studies [ 77 , 90 , 98 , 99 ] reporting on a total of 1937 individuals with SCT and COVID-19.…”

“…when compared to non-SCT pts. n/a 3 (15) 1 n/a 19 (13) 1 Quaresima et al [ 90 ] Italy Obs. 2 (1/1) 51 None Prolonged positivity for SARS-CoV-2, but mostly asymptomatic to mild disease course.…”